Last updated: 2026-09-06 21:33:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Avalo Therapeutics, Inc. (AVTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $19.27, with a market capitalization of $1.04B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $9.54 to $24.27. This page covers its latest market performance, valuation, price trends and company information.
$1.04B | |
$18.81 | |
$9,331.20 | |
$3.39 | |
$19.00 | |
535.49K | |
-- | |
-- | |
$24.27 | |
$9.54 | |
-- | |
-- |
Avalo Therapeutics, Inc. (AVTX) last closed at $19.00 as of 2026-09-04 23:34:00, unchanged from the previous close of $19.00.
During the latest regular trading session, AVTX traded between $3.39 and $9,331.20, with a volume of 535.49K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Avalo Therapeutics, Inc. (AVTX) moved from $19.40 to $19.27, representing a decline of 0.69% ($0.13).
The stock traded between $18.77 and $19.59 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 776.86 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 66.0%
AVTX is currently trading at $19.27, placing it 66.0% of the way from its 52-week low of $9.54 to its 52-week high of $24.27. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 33 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Avalo Therapeutics, Inc. (AVTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.